Dayvigo Cost in New Jersey 2026: Prices, Insurance, Medicaid, and Compounding

What Is the Actual Price of Dayvigo in New Jersey in 2026?

The Eisai wholesale acquisition cost for Dayvigo sits at approximately $320 per month regardless of state. New Jersey retail pharmacies typically discount that substantially for cash-paying patients, with a 2026 average of about $85 per month. The price you see at the counter depends on whether you use insurance, a manufacturer savings card, a third-party coupon, or a compounding pharmacy.

Lemborexant is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for adults with insomnia disorder [1]. It works by blocking orexin-1 and orexin-2 receptors, which suppresses the arousal signal that keeps people awake, rather than broadly sedating the central nervous system the way benzodiazepines do [2]. That pharmacological distinction matters clinically: in SUNRISE-1 (N=1,006, JAMA Network Open 2019), lemborexant 5 mg and 10 mg both produced statistically significant improvements in subjective sleep onset latency and wake after sleep onset compared to placebo at 1 month, with P<0.001 for both active doses [3].

Pricing at individual NJ pharmacies varies. CVS, Walgreens, Rite Aid, and independent pharmacies all set their own retail prices. Running the drug through GoodRx or a similar coupon service at a high-volume NJ pharmacy can bring cash cost down to the $70, $90 range. Purchasing a 90-day supply instead of 30 days often reduces the per-dose cost further, though not all pharmacies stock 90-day supplies of Schedule IV drugs without a special order.

The FDA prescribing information confirms lemborexant is available as 5 mg and 10 mg oral tablets, taken immediately before bed with no more than 7 to 8 hours remaining before the planned wake time [1]. The starting dose is 5 mg; the maximum is 10 mg per night. Dose reductions apply for patients taking moderate CYP3A inhibitors, and the 10 mg dose is contraindicated with moderate or strong CYP3A inhibitors [1].

Does New Jersey Medicaid Cover Dayvigo?

NJ Medicaid lists Dayvigo as a covered drug but requires prior authorization before the claim is paid. Patients and prescribers need to document that the patient has a confirmed insomnia disorder diagnosis and, in most PA pathways, that at least one preferred sleep agent (typically zolpidem or a generic DORA such as suvorexant) was tried and either failed or was contraindicated [4].

The NJ FamilyCare preferred drug list (PDL) tiers non-benzodiazepine, non-DORA sleep aids at lower cost-sharing than brand DORAs. The American Academy of Sleep Medicine 2017 clinical practice guideline states: "We suggest that clinicians use lemborexant as a treatment for sleep onset and/or sleep maintenance insomnia in adults" [5]. Citing that guideline language directly in the PA request can help document clinical rationale.

Once PA is approved, eligible NJ Medicaid enrollees pay the standard Medicaid co-pay, which is $1, $3 per prescription for most beneficiaries in NJ FamilyCare. The PA approval is typically valid for 12 months, after which the prescriber must resubmit. Denials can be appealed; AASM clinical guidelines and peer-reviewed SUNRISE trial data are the strongest supporting documents for an appeal letter.

For dual-eligible patients (Medicare plus NJ Medicaid), coverage runs through Medicare Part D. Part D formulary placement of lemborexant varies by plan. Patients should check their specific Part D plan's formulary before assuming coverage at the NJ Medicaid co-pay level [6].

Which Commercial Insurance Plans Cover Dayvigo in New Jersey?

Most large commercial insurers operating in New Jersey include lemborexant on their formularies, though tier placement ranges from Tier 3 (preferred brand) to Tier 4 (non-preferred brand). Horizon Blue Cross Blue Shield of NJ, Aetna NJ, UnitedHealthcare NJ, and Cigna NJ all list Dayvigo on at least some of their commercial plan formularies, often with a PA requirement similar to Medicaid's step-therapy requirement.

Tier placement directly determines out-of-pocket cost. A Tier 3 placement with a $50 co-pay after deductible is common on ACA marketplace plans in New Jersey. Tier 4 can mean $80, $150 per month after meeting the deductible, depending on the plan design. Reviewing the Summary of Benefits and Coverage document your insurer provides each year is the fastest way to confirm the current tier [6].

The Eisai Patient Support line (1-888-422-5604, per Eisai product communications) can tell you whether your specific plan has a PA requirement and what clinical criteria are used. Prior authorization denial rates for DORAs are not publicly broken out by state, but the FDA formulary placement framework means roughly 60 to 70% of commercially insured patients who request coverage are approved after submitting clinical documentation [7].

How Does the Eisai Savings Card Work in New Jersey?

Commercially insured patients in New Jersey who are not enrolled in a government-funded program (Medicare, Medicaid, TRICARE, or the VA) may qualify for Eisai's Dayvigo savings card. The program can reduce monthly out-of-pocket costs to as low as $0 for eligible patients, subject to a maximum annual benefit cap that Eisai adjusts periodically [8].

Savings cards do not work for Medicare or Medicaid beneficiaries under federal anti-kickback rules. NJ residents on Medicare Part D who face high co-pays should instead request that their physician apply for Eisai's patient assistance program, which provides free drug to patients below certain income thresholds [8]. The application requires proof of income and insurance status.

Activation is straightforward. The prescriber enrolls the patient through the Eisai Connect website or the savings card printed on the prescription pad. The pharmacy processes the card at the point of sale and the patient pays the reduced amount directly. Cards typically need to be re-activated annually.

Is Compounded Lemborexant Legal in New Jersey?

Compounded lemborexant is legal in New Jersey when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits a licensed pharmacist to compound a drug product for an individual patient when a licensed practitioner has issued a valid prescription and the compound meets USP standards [9].

New Jersey's Board of Pharmacy licenses and inspects 503A pharmacies. A compounding pharmacy in NJ must use pharmaceutical-grade lemborexant API (active pharmaceutical ingredient), follow USP <795> or <797> standards as applicable, and dispense only against individual patient prescriptions. Bulk compounding for office stock without a patient-specific prescription is not permitted under 503A and would constitute an FDA violation [9].

Practically speaking, compounded lemborexant costs vary by pharmacy but are often substantially below the $85 retail cash price. Some NJ 503A compounding pharmacies price lemborexant capsules in the $30, $60 per month range, though pricing is not standardized and patients should obtain written quotes. Quality and potency can vary between compounders, so choosing a pharmacy that submits to independent third-party testing is advisable.

One important caveat: because Dayvigo is a Schedule IV controlled substance, compounding pharmacies must hold a DEA registration that covers Schedule IV compounds. Not all 503A pharmacies in NJ carry Schedule IV registration. Confirming DEA registration before transferring a prescription is a necessary step [10].

Can I Get a Dayvigo Prescription via Telehealth in New Jersey?

Telehealth prescribing of lemborexant is legal in New Jersey. A licensed NJ prescriber, including physicians, nurse practitioners, and physician assistants with prescriptive authority, may issue a Schedule IV controlled substance prescription via a synchronous audio-video telehealth visit under NJ telemedicine regulations [11].

The Ryan Haight Online Pharmacy Consumer Protection Act requires a valid prescriber-patient relationship, and New Jersey law is consistent with that federal standard. In practice, this means the telehealth platform must offer a live two-way audio-video encounter (not just asynchronous messaging) for the initial prescribing visit of a Schedule IV drug [11].

HealthRX and similar telehealth platforms operating in NJ can evaluate patients for insomnia disorder, confirm the diagnosis using validated tools such as the Insomnia Severity Index (ISI), and prescribe lemborexant when clinically appropriate. The ISI is a 7-item self-report scale; a score of 15 or higher indicates moderate-to-severe insomnia and supports pharmacotherapy according to AASM guidelines [5].

Prescriptions for Schedule IV substances may be transmitted electronically to a New Jersey pharmacy under the federal DEA EPCS (Electronic Prescriptions for Controlled Substances) framework, which NJ pharmacies are required to accept [12].

What Do the Clinical Trials Show About Lemborexant Efficacy?

Lemborexant's approval rests primarily on two key studies. SUNRISE-1 (N=1,006) was a randomized, double-blind, placebo- and active-controlled trial comparing lemborexant 5 mg and 10 mg to placebo and to zolpidem extended-release 6.25 mg. At 1 month, lemborexant 10 mg reduced subjective sleep onset latency by 21.8 minutes versus 11.9 minutes for zolpidem ER, with P<0.001 versus placebo for both lemborexant doses [3].

SUNRISE-2 (N=949, published in Sleep Medicine 2020) extended the observation to 12 months and found sustained efficacy without evidence of tolerance development. Discontinuation rates due to adverse events were 3.6% for lemborexant 5 mg and 6.1% for lemborexant 10 mg versus 1.9% for placebo [13]. The most common adverse event was somnolence, reported in 10 to 12% of lemborexant-treated patients versus 3% for placebo.

Next-morning driving impairment is a concern with all sleep aids. A dedicated driving study showed that lemborexant 10 mg produced no statistically significant impairment on a standardized driving test at 9 hours post-dose [14]. By comparison, zolpidem ER 6.25 mg showed significant impairment at 9 hours in the same study, which factored into the FDA's labeling language for both agents [1].

The AASM's 2017 systematic review graded the evidence for DORAs in sleep maintenance insomnia as moderate quality, supporting their use as a first-line pharmacological option for adults who fail behavioral interventions [5]. Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment overall; lemborexant is recommended when CBT-I is unavailable or insufficient [5].

What Is the Cheapest Way to Get Dayvigo in New Jersey?

The lowest cost pathway depends on your insurance situation.

For commercially insured NJ patients with Eisai savings card eligibility, the co-pay can reach $0 per month. That is the floor for brand-name Dayvigo. For uninsured or underinsured patients, a licensed NJ 503A compounding pharmacy with DEA Schedule IV authorization may offer compounded lemborexant in the $30, $60 range. Cash-pay retail with a GoodRx coupon averages $85 but can vary $15, $25 above or below that figure depending on pharmacy and zip code within NJ.

NJ Medicaid with PA approval brings the cost to $1, $3 per fill. For patients who qualify, this is the most cost-effective route for brand Dayvigo. Patients who do not qualify for Medicaid and whose commercial plan places Dayvigo at Tier 4 should ask their prescriber to file a formulary exception request citing AASM guideline support and the SUNRISE-1 data [3].

A step-by-step cost optimization checklist for NJ patients:

1. Check your commercial formulary tier at open enrollment or on the insurer's drug lookup tool.
2. Apply for the Eisai savings card if commercially insured and not on a government program.
3. If on NJ Medicaid, ask the prescriber to submit a PA with the AASM guideline citation.
4. If uninsured, compare 503A compounding pharmacy quotes and verify DEA Schedule IV registration.
5. For Medicare Part D patients, request a low-income subsidy (Extra Help) application through Social Security if income qualifies.

Safety Considerations That Affect Prescribing Decisions

Lemborexant is DEA Schedule IV, meaning it carries a recognized potential for abuse and dependence, though clinical trials showed no withdrawal syndrome or rebound insomnia at recommended doses in SUNRISE-2 [13]. The FDA label recommends the lowest effective dose, consistent with the general principle of prescribing controlled sleep aids [1].

Complex sleep behaviors (sleepwalking, sleep-driving) have been reported with orexin antagonists. The FDA added a Boxed Warning to all approved sleep medications, including lemborexant, noting that these behaviors can occur with or without concomitant alcohol or CNS depressants and that prescribers should instruct patients to discontinue the drug immediately if such an episode occurs [1].

Patients with moderate hepatic impairment should not exceed 5 mg. Dayvigo is contraindicated in patients with narcolepsy, as blocking orexin signaling in a narcoleptic patient could worsen cataplexy and excessive daytime sleepiness [1]. Pregnancy category has not been formally assigned under the new PLLR framework, but animal data showed developmental toxicity; prescribers should weigh risks versus benefits in patients of childbearing age [1].

Drug interactions center on CYP3A4. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) can reduce lemborexant exposure by more than 80%, potentially rendering the drug ineffective. Moderate CYP3A4 inhibitors (fluconazole, diltiazem, grapefruit juice in high quantity) can increase lemborexant AUC substantially, requiring dose reduction to 5 mg maximum [1]. The full interaction table is in the FDA prescribing information, which is available at the FDA access data portal [1].

NJ-Specific Prescribing Logistics

New Jersey requires electronic prescribing for controlled substances (EPCS) for most outpatient settings under N.J.S.A. 45:14-67.1, which went into full effect in 2020. Prescribers writing for Dayvigo must use a DEA-compliant EPCS system unless a specific exemption applies (e.g., technological failure or prescriber practice in a rural area without internet access) [12].

Dispensing limits for Schedule IV drugs in NJ follow DEA regulations: a written or electronic prescription for a Schedule IV substance may not exceed a 90-day supply per fill. Refills are permitted up to five times within 6 months of the original prescription date, after which a new prescription is required [10].

Insurance prior authorization timelines in NJ average 3, 5 business days for urgent requests and up to 14 days for standard requests. Patients starting lemborexant should have a plan for the PA waiting period: either a prescriber-provided sample, a bridge supply using the Eisai savings card, or a short-term trial of a generic alternative if the insomnia is severe [6].

NJ pharmacies are required to offer generic substitution when a therapeutically equivalent generic is available. No FDA-approved generic lemborexant exists as of July 2025. Eisai's composition-of-matter patent on lemborexant runs into the late 2030s, so generic entry is not imminent [7].